Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US: Novartis a 'repeat' kickback offender

This article was originally published in Scrip

Executive Summary

Just three years after agreeing to pay $422.5 million to settle fraud charges involving kickbacks, Novartis was accused by US federal prosecutors this week of "using the lure of kickbacks disguised as rebates" to convince pharmacists to switch thousands of kidney transplant patients to the Swiss firm's antirejection medicine Myfortic (mycophenotic acid) from Roche's CellCept (mycophenolate mofetil) or the much cheaper generic forms of both drugs.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel